Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Orelabrutinib in r/r CNSL (SELINA)
NCT07191431Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in central nervous system lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Objective Response Rate at 6 months. Started Sep 2025; status: recruiting.
02
Drugs
selinexor
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on NCT07191431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191431.